Segment, Geographic and Other Revenue Information - Income Statement Narrative (Details) - USD ($) $ in Millions		3 Months Ended	12 Months Ended
		Sep. 27, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
Revenues denominated in Euros			$ 632	$ 593	$ 710
Gain (loss) related to litigation settlement	[1]		(14)	0	(10)
Insurance recoveries					2
Identifiable intangible asset impairment charges	[2]		1	2	7
Foreign currency loss related to Venezuela revaluation	[3]		0		0
Net gain on sale of assets	[4]		26	0	9
Certain Significant Items
Segment Reporting Information [Line Items]
Stand-up costs			23	118	168
Charges to operating model			10
Insurance recoveries			1		2
Identifiable intangible asset impairment charges			1
Foreign currency loss related to Venezuela revaluation				93
Impairment charge				3	6
Investor related costs				3	5
Net gain on sale of assets					3
Additional depreciation asset restructuring					1
Europe, Africa, and Middle East (EuAfME)
Segment Reporting Information [Line Items]
Restructuring charges					12
Manufacturing, Research, Corporate
Segment Reporting Information [Line Items]
Restructuring charges					6
Employee Severance | Certain Significant Items
Segment Reporting Information [Line Items]
Restructuring charges					2
Mexico
Segment Reporting Information [Line Items]
Insurance recoveries		$ 1
Mexico | Certain Significant Items
Segment Reporting Information [Line Items]
Gain (loss) related to litigation settlement			14		13
Insurance recoveries					1
Netherlands
Segment Reporting Information [Line Items]
Pension settlement charge					4
Netherlands | Certain Significant Items
Segment Reporting Information [Line Items]
Pension settlement charge					4
In Process Research and Development
Segment Reporting Information [Line Items]
Identifiable intangible asset impairment charges					6
In Process Research and Development | Certain Significant Items
Segment Reporting Information [Line Items]
Identifiable intangible asset impairment charges				2
Product rights
Segment Reporting Information [Line Items]
Net gain on sale of assets					$ 2
Zoetis Initiatives | Certain Significant Items
Segment Reporting Information [Line Items]
Restructuring charges			$ 10	$ 373

[1] In July 2014 and December 2016, we reached commercial settlements with several large poultry customers in Mexico associated with specific lots of a Zoetis poultry vaccine. Although there have been no quality or efficacy issues with the manufacturing of this vaccine, certain shipments from several lots in Mexico may have experienced an issue in storage with a third party in Mexico that could have impacted their efficacy. We issued a recall of these lots in July 2014 and the product is currently unavailable in Mexico. For 2016, includes a $14 million charge related to the commercial settlement in Mexico for these products. For 2014, includes a $13 million charge recorded in the second quarter of 2014, which was partially offset by a $1 million insurance recovery recorded in the third quarter of 2014, related to the commercial settlement in Mexico. We do not expect any significant additional charges related to this issue. For 2014, also includes an insurance recovery of other litigation-related charges of $2 million.

[2] In 2016, the intangible asset impairment charge represents an impairment of finite-lived trademarks related to a canine pain management product. In 2015, charges include the impairment of acquired IPR&D assets related to the termination of a canine oncology project. In 2014, charges primarily include (i) approximately $6 million of IPR&D assets related to a pharmaceutical product for dogs acquired with the Fort Dodge Animal Health (FDAH) acquisition in 2009, as a result of the termination of the development program due to a re-assessment of economic viability; and (ii) approximately $1 million related to finite-lived developed technology rights and IPR&D due to negative market conditions and the re-assessment of economic viability.

[3] For additional information, see Note 7. Foreign Currency Loss Related to Venezuela Revaluation.

[4] In 2016, represents the net gain on sales of certain manufacturing sites and products related to our operational efficiency initiative. In 2014, represents the net gain on sale of land in our joint venture in Taiwan of $6 million and the net gain on the government-mandated sale of certain product rights in Argentina and China that were associated with the FDAH acquisition in 2009 of $3 million.